Reuters logo
BRIEF-Living Cell Technologies meets 3 of 4 endpoints in study of NTCELL for Parkinson's disease ​
November 9, 2017 / 10:51 PM / 15 days ago

BRIEF-Living Cell Technologies meets 3 of 4 endpoints in study of NTCELL for Parkinson's disease ​

Nov 10 (Reuters) - Living Cell Technologies Ltd

* ‍Results of co’s Phase IIB clinical study of NTCELL for Parkinson’s Disease have been unblinded​

* ‍Phase IIB clinical study of NTCELL for Parkinson’s disease released, 3 of 4 primary endpoints​ met

* “‍Disappointed that efficacy primary endpoint has not been met”​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below